I would like to start a conversation about these two future competitors in the PAH space. Tyvaso DPI is the first inhaled dry powder prostacyclin to market, while Yutrepia seemingly will be the second. Does anyone know how exactly they differ? I do know that Tyvaso DPI uses Technosphere powder, and Yutrepia uses something called PRINT Technology. Do the MNKD shorts see some advantage to Yutrepia? If so, what might it be?
I believe that the CEO of Liquidia is a former VP of United Therapeutics, as well. Any comments on my research?